# 甲状腺疾患市場 > 甲状腺疾患市場調査レポート タイプ別（甲状腺機能低下症および甲状腺機能亢進症）、治療法（薬物療法、放射性ヨウ素療法、手術）、投与経路（経口、静脈内など）、エンドユーザー（病院、診療所など）および地域（アメリカ、ヨーロッパ、アジア太平洋、中東およびアフリカ）ごとの情報 - 2035までの予測 - **Forecast Period:** 2025 - 2035 - **CAGR:** 4.2% - **2024:** $ 2.51 Billion - **2025:** $ 2.62 Billion - **2035:** $ 3.95 Billion - **Key Players:** AbbVie(US), Bristol-Myers Squibb (US), Eli Lilly and Company (US), Merck & Co. (US), Novartis (CH), Pfizer(US), Sanofi (FR), Takeda Pharmaceutical Company (JP), Amgen (US) **Report ID:** MRFR/Pharma/2031-CR · **Pages:** 118 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** August 24, 2026 **URL:** https://www.marketresearchfuture.com/reports/thyroid-disorder-market-2747 --- ## Market Summary ## **Global Thyroid Disorder Market Overview** Thyroid Disorder Market Size was valued at USD 2.41 Billion in 2023. The Global Thyroid Disorder industry is projected to grow from USD 2.53 Billion in 2024 to USD 3.55 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 3.87% during the forecast period (2024 - 2032). These figures are indeed up-and-coming and ensure that the market has vast scope in the coming future. The disorders that arise due to improper functioning of thyroid glands are referred to as thyroid disorders. This gland is located at the middle level of the lower neck and is responsible for the secretion of the hormone known as thyroid hormone. The primary function of this hormone is to regulate the activities related to metabolism in the body. If an individual suffers from thyroid disorders, it leads to an increased or decreased level of hormones responsible for metabolism in the body.  Such elevation or decrease in thyroid disorder symptoms causes hypothyroidism, hyperthyroidism, and many more. The main elements driving the thyroid disorder market are the fact that people are getting more awareness about the thyroid disorder causes and the medical health policies, making them more aware of their health. But factors that restrict or push back the market are the pensive procedures involved are relatively high and also have known to cause side effects. ### **COVID-19 analysis ** The entire world has witnessed an unforgettable time with the COVID 19 pandemic attack. Lives for everyone have taken a turn. Businesses have been affected the most, and getting back to normal would take some time for sure. Even after utilizing resources and human resources, each company would require mentorship and guidance to ensure that they are on the correct track and cope with whatever they have lost in a short period.  The reports prepared provide insights about all thin depth analyses carried out by the experts over the last few months. The reports have a particular focus on the effect that the pandemic has bought on the companies. This is one of those cost-effective measures that have expertise attached to them yet are budget-friendly. They also provide the current situation of the market in various countries. ### **Market Dynamics** Thyroid-related disorders have been increasing each year. Thyroid disorder causes include bad eating habits or other related factors. According to recent research, more than 12% of the total population in the united states is suffering thyroid-related disorder, which is, in fact, a considerable figure. It's just in the states, but other developed and developing countries like India, UK, and many more have also seen a similar rise in the figures. Hypothyroidism is prevalent in a developed region like the United Kingdom, where around 27.7% of the total population suffers from the same. Type-increasing figures have given a boost to the thyroid disorder market size in the last few years. It has also been studied that thyroid-related disorders are even more common than diseases like cancer. ### **Regulatory im plications** Marketing, production, and the distribution of the thyroid disorder market are regulated by FDA or food and drug administration. In Europe, it is controlled by EMA or European Medicines Agency. In a recent study, it has been revealed that FDA and EMA both have almost the same criteria for regulations of the products and services in the market. These organizations are being planned to make sure that drugs can be made available to people at many affordable rates. These keep a check of how the service and or products are being marketed and manufactured. The bodies that regulate the fact that the users with thyroid disorder symptoms get everything at affordable prices are not compromises on the quality have proved to bring sustainability and stability in the thyroid disorder market. ## **Thyroid Disorder Market Segmentation** Various segments in which the market has been divided are ### **Thyroid Disorder Type Outlook** By type, the thyroid disorder market is sub-divided into: • Hypothyroidism • Hyperthyroidism ### **Thyroid Disorder Treatment Outlook** There is three subdivision in the thyroid gland disorders treatment market : • Medications • Surgery • Radioactive iodine therapy ### **Thyroid Disorder Route of Administration Outlook** There are a further three sub-divisions based on the route of administration. These are: • Intravenous • Oral • Other ### **Thyroid Disorder End-User Outlook** These are further subdivided into three subtypes. These are: • Clinics • Hospitals • Others ### **Thyroid Disorder Regional Outlook** The market is divided into the Americas, the Asia Pacific, the middle east, Africa, and Europe based in the regions.  The Americas dominate the** **thyroid disorder market size, mainly because of the high population suffering from one of the other thyroid-related disorders. According to a survey conducted in the year 2016, almost 13 million people suffer from these disorders. There has been advancement in medicines and thyroid disorder treatment procedures for thyroid-related conditions as well. Moreover, awareness among the population has to lead to growth and the market too. The region that bags the second place is that of Europe. An increase in the number of pharmaceutical companies that export their products outside Europe has contributed to the market's growth to a great extent. Research and the development of medicines for thyroid-related disorders have been a main task foremost in Europe. Not only this, but there has been a sharp increase in the investments made in pharmaceutical logistics, which is also a critical factor in the growth of the market in Europe as per the latest thyroid disorder case study. The fastest-growing thyroid disorder market share is that of Asia Pacific, which can be considered the destinations outsourced for [clinical trials](../../../reports/clinical-trials-market-7787), testing, and manufacturing of drugs. Sideways, third-party pharmaceutical companies are also looking to expand their business in developing countries like India, Singapore, China.  ## **Competitive landscape** Here is a list of the key contenders of the thyroid disorder market according to the latest thyroid disorder case study**. **Pfizer Inc (US) can be considered the top-notch company that leads the thyroid disorder market.  The companies that also have a significant role in the market are: - Pfizer Inc (US) - [AbbVie](https://www.rxabbvie.com/pdf/armour_thyroid_pi.pdf?_ga=2.51145898.2047901195.1721726560-1204967136.1721726560&_gl=1*1whpisc*_ga*MTIwNDk2NzEzNi4xNzIxNzI2NTYw*_ga_5LEXD56YGK*MTcyMTcyNjU2OC4xLjEuMTcyMTcyNjYzOS4wLjAuMA..*_fplc*d0VGOGcweVl3T2Y2MFJRNnlhOWZIR3QycmN5WVI2YnRiRDBTQnVzVHVuVGJaRiUyQnlhRWY4OWJyQmk5a2RybUtYalp6Z21qa3BvZkVuRCUyQklRcTViY0NSckVPWjNnM2dKTFlpSW9OMnhEM05KbEUlMkJjSCUyRlFTYzdQM2lGNXdWNlElM0QlM0Q.) Inc (US) - Merck KGaA (Germany) - Abbott Laboratories (US) - GlaxoSmithKline PLC (UK) - [RLC Labs](https://www.rlclabs.com/i-throid.html) (US) - Mylan NV (US) As can be seen, most of the key players are from the united states. Reason being that it dominates the thyroid disorder treatment market for the highest population suffering from such diseases. The strategies that all of them have been following to reach today include product development, expansion, and innovation. ## **Recent developments** Recent development in the thyroid disorder market are • In November 2015, a program that focuses on managing the daily routine of those having the life-long condition of hypothyroidism was launched by Abbie under Good Morning Hypothyroidism (GMH). • In October 2016, ThyroTest was introduced by Abbott acquired Alere Inc., a service provider organization and a [diagnostic device](../../../reports/portable-diagnostic-devices-market-7218) manufacturer introduced in the market, which is a test to detect hypothyroidism. • In March 2018, an orally available tyrosine kinase inhibitor was discovered by Eisai. • Also, in the same month, it was announced by Eisai Co Ltd and Merck about their strategic collar radiation. They are popularly called MSD after the collaboration. • The commercialization of LENVIMA was also done in the year 2018. ### **Report overview** A market that is all set to reach a CAGR that equals a great figure is the global thyroid disorder market. While the population is experiencing an increased rate of thyroid disorders, the growth that the thyroid disorder market share has seen and is expected to see is tremendous. Rising awareness about the illness is another factor contributing to being the growth of the market.  On the other hand, in developed or underdeveloped countries, the market's development is sluggish due to the availability of inadequate health facilities, high cost of thyroid gland disorders treatment market, and lack of awareness. The trend and growth of the market are increasing slowly but would take a little time.  ## Market Drivers ### Rising Healthcare Expenditure ### Growing Demand for Targeted Therapies ### Rising Incidence of Thyroid Disorders ### Advancements in Diagnostic Technologies ### Increased Investment in Research and Development ## Future Outlook 甲状腺疾患市場は、有病率の増加、in診断の進歩、治療選択肢の強化により、at、4.2%、CAGRから2024から2035に成長すると予測されています。 **New opportunities:** - 遠隔患者モニタリングのための遠隔医療プラットフォームの開発 投資で早期発見のための AI ベースの診断ツール 個別化医療アプローチの拡大で治療プロトコル 2035までに、甲状腺疾患市場は大幅な成長と革新を達成すると予想されます。 ## Regional Market Share Analysis ### North America : Leading Market for Innovation North America is the largest market for thyroid disorders, accounting for approximately 45% of the global market share. The region's growth is driven by increasing prevalence of thyroid diseases, heightened awareness, and advancements in treatment options. Regulatory support from agencies like the FDA facilitates faster drug approvals, enhancing market dynamics. The demand for innovative therapies and personalized medicine is also on the rise, further propelling market growth. The United States is the leading country in this region, with significant contributions from Canada. Major pharmaceutical companies such as AbbVie, Eli Lilly, and Merck & Co. are actively involved in developing and marketing thyroid disorder treatments. The competitive landscape is characterized by a focus on research and development, with companies investing heavily in new therapies to meet the growing demand for effective treatment options. ### Europe : Emerging Market with Growth Potential Europe is witnessing significant growth in the thyroid disorder market, holding approximately 30% of the global share. The increasing incidence of thyroid-related conditions, coupled with rising healthcare expenditure, is driving demand for effective treatments. Regulatory frameworks in countries like Germany and France are supportive of innovative therapies, which enhances market accessibility and patient care. The region is also focusing on preventive healthcare measures, which is expected to further boost market growth. Leading countries in Europe include Germany, France, and the UK, where key players like Novartis and Sanofi are making substantial investments. The competitive landscape is marked by collaborations and partnerships aimed at enhancing product offerings. The presence of well-established healthcare systems facilitates the introduction of new therapies, ensuring that patients have access to the latest treatment options available. ### Asia-Pacific : Rapidly Growing Healthcare Sector The Asia-Pacific region is emerging as a significant player in the thyroid disorder market, accounting for about 20% of the global market share. The growth is driven by increasing awareness of thyroid health, rising disposable incomes, and improvements in healthcare infrastructure. Countries like China and India are witnessing a surge in demand for thyroid treatments, supported by government initiatives aimed at enhancing healthcare access and affordability. Regulatory bodies are also streamlining approval processes for new therapies, fostering market growth. China is the largest market in this region, followed by India, where local and international players are competing to capture market share. Companies like Takeda and Amgen are actively involved in the development of innovative therapies. The competitive landscape is characterized by a mix of multinational corporations and local firms, all striving to meet the growing demand for effective thyroid disorder treatments. This dynamic environment is expected to drive further advancements in the sector. ### Middle East and Africa : Untapped Market with Potential The Middle East and Africa region is gradually emerging in the thyroid disorder market, holding approximately 5% of the global share. The growth is primarily driven by increasing awareness of thyroid health issues and the rising prevalence of thyroid disorders. Government initiatives aimed at improving healthcare access and affordability are also contributing to market expansion. Regulatory bodies are working to enhance the approval processes for new treatments, which is expected to stimulate market growth in the coming years. Leading countries in this region include South Africa and the UAE, where there is a growing presence of international pharmaceutical companies. The competitive landscape is evolving, with both local and The Thyroid Disorder. Companies are focusing on partnerships and collaborations to enhance their product offerings and meet the increasing demand for effective thyroid disorder treatments. ## Competitive Benchmarking The Thyroid Disorder Market is characterized by a dynamic competitive landscape, driven by increasing prevalence rates and a growing awareness of thyroid-related health issues. Key players such as AbbVie (US), Eli Lilly and Company (US), and Novartis (CH) are strategically positioned to leverage innovation and expand their market presence. AbbVie (US) focuses on developing novel therapies, while Eli Lilly and Company (US) emphasizes partnerships to enhance its product portfolio. Novartis (CH) is actively pursuing regional expansion, particularly in emerging markets, which collectively shapes a competitive environment that is increasingly focused on patient-centric solutions and advanced therapeutic options. In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Thyroid Disorder Market appears moderately fragmented, with several key players exerting influence over various segments. This fragmentation allows for a diverse range of treatment options, yet the collective strategies of these companies indicate a trend towards consolidation and collaboration, particularly in research and development initiatives. In August 2025, AbbVie (US) announced a strategic partnership with a leading biotechnology firm to co-develop a new class of thyroid hormone replacement therapies. This collaboration is expected to accelerate the development timeline and enhance the therapeutic efficacy of treatments, thereby positioning AbbVie (US) as a frontrunner in the market. The strategic importance of this partnership lies in its potential to address unmet medical needs and improve patient outcomes, which is increasingly becoming a focal point in the industry. In September 2025, Eli Lilly and Company (US) launched a digital health platform aimed at improving patient engagement and adherence to thyroid disorder treatments. This initiative reflects a broader trend towards digitalization in healthcare, where technology is utilized to enhance patient experiences and outcomes. The strategic significance of this move is profound, as it not only strengthens Eli Lilly's (US) market position but also aligns with the growing demand for integrated healthcare solutions that prioritize patient-centric care. In July 2025, Novartis (CH) expanded its manufacturing capabilities in Asia to meet the rising demand for thyroid medications in the region. This expansion is indicative of Novartis's (CH) commitment to regional growth and its strategy to ensure supply chain reliability. The implications of this move are substantial, as it positions Novartis (CH) to better serve a burgeoning market while also mitigating potential supply chain disruptions that could arise from global uncertainties. As of October 2025, current competitive trends in the Thyroid Disorder Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in treatment protocols. Strategic alliances are shaping the landscape, fostering innovation and enhancing the development of advanced therapies. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition towards a focus on innovation, technological advancements, and the reliability of supply chains, thereby ensuring that companies remain agile and responsive to the ever-changing healthcare environment. ## Recent News & Developments Recent development in the thyroid disorder market are • In November 2015, a program that focuses on managing the daily routine of those having the life-long condition of hypothyroidism was launched by Abbie under Good Morning Hypothyroidism (GMH). • In October 2016, ThyroTest was introduced by Abbott acquired Alere Inc., a service provider organization and a [diagnostic device](../../../reports/portable-diagnostic-devices-market-7218) manufacturer introduced in the market, which is a test to detect hypothyroidism. • In March 2018, an orally available tyrosine kinase inhibitor was discovered by Eisai. • Also, in the same month, it was announced by Eisai Co Ltd and Merck about their strategic collar radiation. They are popularly called MSD after the collaboration. • The commercialization of LENVIMA was also done in the year 2018. ## Report Scope | MARKET SIZE 2024 | 2.511(USD Billion) | | --- | --- | | MARKET SIZE 2025 | 2.617(USD Billion) | | MARKET SIZE 2035 | 3.948(USD Billion) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.2% (2024 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Billion | | Key Companies Profiled | Market analysis in progress | | Segments Covered | Market segmentation analysis in progress | | Key Market Opportunities | Integration of telemedicine and digital health solutions in the Thyroid Disorder Market. | | Key Market Dynamics | Rising prevalence of thyroid disorders drives demand for innovative treatment options and enhanced diagnostic technologies. | | Countries Covered | North America, Europe, APAC, South America, MEA | ## Frequently Asked Questions **Q: 2035による甲状腺疾患市場の予想市場評価はいくらですか?** A: 甲状腺疾患市場は、2035による評価額が3.948 USD Billionに達すると予測されています。 **Q: 甲状腺疾患市場で2024 の市場評価はいくらでしたか？** A: In 2024、甲状腺疾患市場はで2.511 USD Billion と評価されました。 **Q: 予測期間2025 - 2035中の甲状腺疾患市場の予想CAGRは何ですか?** A: 予測期間2025 - 2035中の甲状腺疾患市場の予想CAGRは4.2%です。 **Q: どの企業が甲状腺疾患市場の主要なプレーヤーと考えられていますか?** A: 甲状腺疾患市場の主要企業でには、アッヴィ、ブリストル マイヤーズ スクイブ、イーライ リリー アンド カンパニー、メルク アンド カンパニーが含まれます。 **Q: 2035 による甲状腺機能低下症および甲状腺機能亢進症セグメントの予想収益はいくらですか?** A: 2035 までに、甲状腺機能低下症の予測収益は 2.368 USD Billion となり、甲状腺機能亢進症の収益は 1.58 USD Billion に達すると予想されます。 **Q: 甲状腺疾患市場とその予測収益にはどのような治療オプションがありますか?** A: 2035 による治療オプションの予測収益には、投薬で1.949 USD Billion、手術で1.174 USD Billion、放射性ヨウ素療法で0.825 USD Billion が含まれます。 **Q: 投与経路は甲状腺疾患市場にどのような影響を与えますか?** A: 2035 までに、経口投与経路は 1.951 USD Billion を生成すると予測されており、甲状腺疾患市場におけるその重要な役割を示しています。 **Q: 2035 による甲状腺疾患市場のさまざまなエンドユーザーでの予想収益はいくらですか?** A: 2035 までに、病院は 1.563 USD Billion、クリニックは 1.174 USD Billion、その他は 1.211 USD Billion を生成すると予想されます。 **Q: 甲状腺疾患市場の成長は他のヘルスケア分野とどのように比較されますか?** A: 甲状腺疾患市場の成長率は、CAGRから4.2%と予測されており、他のヘルスケア分野と比較して着実な拡大を示唆しています。 **Q: 今後数年間の甲状腺疾患市場inの成長に影響を与える可能性のある要因は何ですか?** A: 治療オプションの進歩や甲状腺疾患に対する意識の高まりなどの要因は、甲状腺疾患市場の成長に影響を与える可能性があります。 --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/thyroid-disorder-market-2747*